Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AADvac1 in Progressive Supranuclear Palsy
NCT07217665Phase 2Enrolling by invitation
- Start
- Jul 2026
- Primary completion
- Sep 2030
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AADvac1 in progressive supranuclear palsy (PSP). Started Jul 2026; status: enrolling by invitation.
02
Drugs
AADvac1
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07217665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217665.